Opioid Antagonist Low Dose denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for opioid antagonist low dose are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Cites "Not FDA-Approved" for Low-Dose Opioid Antagonists — and Why This Is Frequently Contestable

This denial type typically arises in one of two scenarios: (1) the plan is treating an off-label use of an FDA-approved compound as if the compound itself lacks approval, or (2) a compounded preparation is being prescribed when no commercially manufactured product at that specific formulation exists. These are legally and clinically distinct situations that require different appeal strategies.

For scenario (1), it is important to understand that off-label prescribing of FDA-approved drugs is both legal and common — the FDA regulates drug approval, not the practice of medicine. Most plan definitions of "not FDA-approved" are intended to exclude unapproved compounds, not off-label uses of approved drugs. Many BCBS plans and state insurance regulations explicitly require coverage of off-label uses that are supported by recognized medical compendia or peer-reviewed literature.

For scenario (2) involving compounded preparations, the appeal strategy focuses on demonstrating that the compounded formulation is medically necessary because no commercially available equivalent meets the patient's clinical needs.

## Your Federal Appeal Rights

ACA §2719 and ERISA §503 provide for internal appeal and binding external review by an IRO. The external-review window is generally available within approximately four months. Expedited review is available for urgent situations.

## Concrete Appeal Steps

1. Clarify the basis of the denial — confirm whether BCBS is claiming the underlying compound lacks FDA approval, or that the specific use is off-label. These require different responses. 2. Cite the FDA approval status — if the compound is FDA-approved, document this clearly in the appeal. 3. Invoke the off-label coverage provision — if your plan or state requires coverage of off-label uses supported by compendia or peer-reviewed evidence, cite that provision explicitly. 4. File the internal appeal and escalate to external review if denied.

## Documentation to Gather

• FDA approval documentation: the FDA-approved prescribing information (package insert) for the underlying compound, confirming its approval status.
• Compendia or literature support for off-label use: references to recognized drug compendia (e.g., AHFS, Micromedex, NCCN Drugs and Biologics Compendium) or peer-reviewed publications supporting the prescribed use — your prescriber can assist in identifying these.
• Prescriber's medical-necessity letter: explaining the clinical basis for the prescribed use and its support in current medical practice.
• Plan's off-label coverage policy: if your plan or state mandates coverage of compendium-supported off-label uses, include the relevant policy language.
• For compounded preparations: documentation that no commercially available product meets the clinical need (e.g., required dose range not commercially available).

## Criteria-Mapping Structure

Obtain the BCBS policy definition of "not FDA-approved" and the plan's off-label use coverage provision. Build a table demonstrating that the prescribed use either falls within the FDA approval or satisfies the off-label coverage criteria — with each element addressed by a specific document or citation.